Neurophth Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $62.5M
Latest Deal Amount
  • Investors
  • 12

Neurophth General Information

Description

Developer of gene therapies for ophthalmological disorders. The company's therapies aim to cure disorders such as Leber's hereditary optic neuropathy caused by genetic mutation, enabling physicians to prescribe more effective treatments to their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • C270-C271, 3rd Floor, Building B1, Optics Valley Biological City, No.666 Gaoxin Avenue
  • Donghu New Technology Development Zone
  • Wuhan, Hubei 430000
  • China
+86 027 0000 0000

Neurophth Timeline

2019202020212022
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurophth Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 22-Nov-2021 $62.5M 00000 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B) 05-Feb-2021 000.00 000.00 00000 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A) 17-Dec-2019 $18.5M $20.8M 000.00 Completed Pre-Clinical Trials
1. Early Stage VC 01-Jul-2018 $2.32M $2.32M 000.00 Completed Startup
To view Neurophth’s complete valuation and funding history, request access »

Neurophth Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of gene therapies for ophthalmological disorders. The company's therapies aim to cure disorders such as Leber'
Drug Discovery
Wuhan, China
00000
00000000000 00000

000 0000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu f
0000000000000
Ann Arbor, MI
00 As of 0000
000.00
00000000000 000.00

000000 0

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
0000 000000000
Shanghai, China
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurophth Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
000000 000000 Venture Capital-Backed Shanghai, China 00 00000 00000000000 00000
000000000 Formerly VC-backed London, United Kingdom 000 00000 000000&0 00000
You’re viewing 3 of 3 competitors. Get the full list »

Neurophth Executive Team (5)

Name Title Board Seat Contact Info
Alvin Luk Ph.D Chief Executive Officer
Su Zhang Chief Financial Officer
Su Xiao Chief Technology Officer & Chief Operating Officer
Bin Li Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

Neurophth Board Members (1)

Name Representing Role Since
Bin Li Neurophth Chairman 000 0000
To view Neurophth’s complete board members history, request access »

Neurophth Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CMB International Capital Asset Manager Minority 000 0000 000000 0
CMG SDIC Fund Venture Capital Minority 000 0000 000000 0
Sunshine Insurance Group PE-Backed Company Minority 000 0000 000000 0
Grand Mount Capital Venture Capital Minority 000 0000 000000 0
Guofang Investment Fund of Funds Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »